Cardio Diagnostics Holdings Inc (CDIO) - Total Assets
Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) holds total assets worth $7.77 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CDIO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cardio Diagnostics Holdings Inc - Total Assets Trend (2020–2025)
This chart illustrates how Cardio Diagnostics Holdings Inc's total assets have evolved over time, based on quarterly financial data. See CDIO net asset value for net asset value and shareholders' equity analysis.
Cardio Diagnostics Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cardio Diagnostics Holdings Inc's total assets of $7.77 Million consist of 76.2% current assets and 23.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.8% |
| Accounts Receivable | $8.13K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $873.18K | 11.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Cardio Diagnostics Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cardio Diagnostics Holdings Inc (CDIO) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardio Diagnostics Holdings Inc's current assets represent 76.2% of total assets in 2025, an increase from 55.1% in 2020.
- Cash Position: Cash and equivalents constituted 65.8% of total assets in 2025, up from 53.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 44.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 11.2% of total assets.
Cardio Diagnostics Holdings Inc Competitors by Total Assets
Key competitors of Cardio Diagnostics Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Cardio Diagnostics Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.79 | 13.92 | 0.43 |
| Quick Ratio | 9.79 | 13.92 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.32 Million | $8.16 Million | $-46.15K |
Cardio Diagnostics Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Cardio Diagnostics Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -26.8% |
| Total Assets | $7.77 Million |
| Market Capitalization | $4.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cardio Diagnostics Holdings Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cardio Diagnostics Holdings Inc's assets decreased by 26.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual total assets of Cardio Diagnostics Holdings Inc from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.77 Million | -26.84% |
| 2024-12-31 | $10.62 Million | +137.89% |
| 2023-12-31 | $4.46 Million | -28.60% |
| 2022-12-31 | $6.25 Million | +467.11% |
| 2021-12-31 | $1.10 Million | +146.88% |
| 2020-12-31 | $446.38K | -- |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more